ShallowBench: Benchmarking Generative Drug Design Models on Shallow-Pocket Targets

Researchers introduce ShallowBench, a curated benchmark of 5,780 shallow-pocket protein targets, revealing that current generative AI drug design models struggle with low-concavity binding sites common in challenging oncology targets like KRAS and MYC. The benchmark highlights a critical gap in generative biology that requires new architectural innovations to address historically undruggable targets.

The emergence of ShallowBench addresses a fundamental limitation in computational drug discovery that has constrained generative AI's practical impact. While generative models have excelled at designing ligands for deep binding pockets—the traditional focus of structure-based drug design—they systematically underperform on shallow-pocket targets that characterize some of the most clinically valuable yet difficult-to-drug proteins. This gap matters because oncology targets like KRAS and MYC represent enormous market opportunities precisely because they were previously considered undruggable.

The research builds on years of progress in generative models for molecular design, where deep learning has displaced traditional computational chemistry methods. However, generative models optimized on historically successful drug targets naturally inherit the biases of the training data. ShallowBench's rigorous isolation of low-concavity interfaces using Alpha Shape geometry provides a diagnostic tool that quantifies model performance on a clinically relevant but underrepresented problem space.

For the biotech and pharmaceutical industry, this benchmark creates immediate pressure on AI platform companies to address the shallow-pocket limitation. Companies developing generative drug design tools face a credibility gap if they cannot demonstrate competence on these challenging targets. Investors in computational biology startups should scrutinize whether their technical approaches account for binding site topology variations. The research also signals that the next wave of competitive advantage in AI-driven drug discovery lies not in raw model scale but in architectural innovations specifically designed for complex binding geometries.

• →Current generative AI drug design models show weaker performance on shallow-pocket targets, limiting their applicability to historically undruggable oncology proteins
• →ShallowBench provides a rigorous, curated benchmark of 5,780 low-concavity targets that isolates a previously undercharacterized challenge in generative biology
• →The benchmark reveals that generative model performance depends critically on binding pocket geometry, not just ligand-protein interactions
• →New architectural innovations or loss functions are necessary to extend generative drug design capabilities to shallow binding interfaces
• →Biotech and pharma companies face pressure to validate generative AI tools against challenging targets like KRAS and MYC to justify clinical relevance